This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Sign In
Don’t have an account?
  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Bayer cross
BAYER FOR PROFESSIONALSYour Resource Portal
  • Ophthalmology
  • EYLEA® (aflibercept) 8 mg
  • EYLEA® (aflibercept) 2 mg
  • Oncology
  • Nubeqa® (darolutamide)
  • Xofigo®▼ (radium-223 dichloride)
  • Cardiology
  • Beyonttra®▼ (acoramidis)
  • Kerendia®▼ (finerenone)
  • Xarelto® (rivaroxaban)
  • Women's Health
  • Angeliq® (1mg estradiol hemihydrate and 2mg drospirenone)
  • Jaydess®▼ (13.5mg levonorgestrel)
  • Kyleena® (19.5mg levonorgestrel)
  • Mirena® (52mg levonorgestrel)
  • Qlaira® (estradiol valerate/dienogest)
  • Service Optimisation & Formularies
  • Risk Minimisation Materials
  • Ophthalmology
  • Oncology
  • Cardiology
  • Women's Health
  • Ophthalmology Resources
  • Oncology Resources
  • Cardiology Resources
  • Women's Health Resources
  • Ophthalmology Events & On Demand Webinars
  • Oncology Events & On Demand Webinars
  • Cardiology Events & On Demand Webinars
  • Women's Health Events & On Demand Webinars
  • Ophthalmology Learning Zone
  • Oncology Learning Zone
  • Cardiology Learning Zone
  • Women's Health Learning Zone
  • Ophthalmology Podcasts
  • Oncology Podcasts
  • Cardiology Podcasts
  • Women's Health Podcasts
closesearch
Recent Searches
    You are now leaving BayerPro

    The contents and the policies on the website you are visiting is not controlled by the BayerPRO team.
    Do you wish to continue?

    Cell

    Prostate Cancer Events & Webinars

    View more
    ESMO 2024 Shorts Series
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2082, January 2025
    BAUS 2024: Management of CV toxicity and bone health
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2079, January 2025
    BAUS 2024: Urology and Oncology in Partnership
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2080, January 2025
    BAUS 2024: Imaging and nmCRPC
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2081, January 2025